Contrasting BridgeBio Pharma (NASDAQ:BBIO) & Phio Pharmaceuticals (NASDAQ:PHIO)

BridgeBio Pharma (NASDAQ:BBIO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Earnings and Valuation

This table compares BridgeBio Pharma and Phio Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$9.30 million	748.85	-$643.20 million	($2.41)	-15.29
Phio Pharmaceuticals	N/A	N/A	-$10.83 million	($10.92)	-0.15

Phio Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BridgeBio Pharma has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for BridgeBio Pharma and Phio Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0	1	12	0	2.92
Phio Pharmaceuticals	0	0	1	0	3.00

BridgeBio Pharma currently has a consensus price target of $51.67, suggesting a potential upside of 40.21%. Phio Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 139.52%. Given Phio Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than BridgeBio Pharma.

Institutional and Insider Ownership

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BridgeBio Pharma and Phio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-201.53%	N/A	-74.34%
Phio Pharmaceuticals	N/A	-134.57%	-108.39%

Summary

BridgeBio Pharma beats Phio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.